Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis – study site experience based on the therapy of 104 patients-Reference-Cited by-同舟云学术

Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis – study site experience based on the therapy of 104 patients

Published:2016-12-23 Issue:10 Volume:127 Page:859-863
ISSN:0020-7454
Container-title:International Journal of Neuroscience
language:en
Short-container-title:International Journal of Neuroscience

Author:

Lasek-Bal Anetta¹²,Bartoszek Karina²,Steposz Arkadiusz¹²,Puz Przemyslaw¹²,Bal Wieslaw³,Kazibutowska Zofia²

Affiliation:

1. Department of Neurolog, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland

2. Department of Neurology, Professor Leszek Giec Upper Silesian Medical Centre, Medical University of Silesia Hospital No. 7, Katowice, Poland

3. Department of Radiation Oncology and Chemotherapy, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

Publisher

Informa UK Limited

Subject

General Medicine,General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/00207454.2016.1269327

Reference24 articles.

1. Rationale for the use of mitoxantrone in multiple sclerosis

2. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment

3. Mitoxantrone: benefits and risks in multiple sclerosis patients

4. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and management of secondary-progressive multiple sclerosis: time for change;Neurodegenerative Disease Management;2019-12

2. Multiple sclerosis – the remarkable story of a baffling disease;Reviews in the Neurosciences;2019-07-26

3. Design, synthesis and evaluation of an anthraquinone derivative conjugated to myelin basic protein immunodominant (MBP85-99) epitope: Towards selective immunosuppression;European Journal of Medicinal Chemistry;2018-01

4. Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System;Chinese Medical Journal;2017-08-05